• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Biologics research promises to bolster future of medicine

Report: Biologics research promises to bolster future of medicine

March 11, 2013
CenterWatch Staff

America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

The report includes biologics in human clinical trials or under review by the UFDA such as: 338 cancer therapeutics that target several different types of solid tumors, leukemia and lymphoma; 134 vaccines for infectious diseases; 71 medicines for autoimmune diseases including lupus, multiple sclerosis and rheumatoid arthritis; and 58 treatments for cardiovascular disease.

"These medicines reflect the cutting-edge research being conducted across the country by biopharmaceutical companies in order to provide new treatment options to patients," said John J. Castellani, president and CEO of PhRMA.

The biologic medicines now in development make use of a range of new technologies to harness scientific progress. Among the biologic medicines in development are: a genetically-modified virus-based vaccine to treat melanoma; a monoclonal antibody for the treatment of asthma; an antisense therapy for the treatment of leukemia; and a recombinant fusion protein to treat type 2 diabetes.

"In order to realize the full potential of novel biologics to improve human health, it is essential to maintain public policy and regulatory environments to support the research and development that drives biomedical innovation," said Castellani.

The U.S. biopharmaceutical research sector supports nearly four million jobs across the economy, invests billions of dollars in research and development each year, and accounts for nearly 20% of all domestic R&D funded by U.S. businesses generating high-quality, high-wage jobs, powering the U.S. economy, and developing critical new treatments against our most costly and challenging diseases.

The Biologic Medicines in Development report, as well as an overview and other supplementary materials, are available on PhRMA's website.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing